nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—atherosclerosis	0.354	0.678	CbGaD
Pomalidomide—PTGS2—atherosclerosis	0.168	0.322	CbGaD
Pomalidomide—ABCB1—Ezetimibe—atherosclerosis	0.0381	0.152	CbGbCtD
Pomalidomide—ABCB1—Simvastatin—atherosclerosis	0.0354	0.141	CbGbCtD
Pomalidomide—ABCB1—Pravastatin—atherosclerosis	0.0347	0.138	CbGbCtD
Pomalidomide—ABCB1—Lovastatin—atherosclerosis	0.0347	0.138	CbGbCtD
Pomalidomide—CYP3A4—Rosuvastatin—atherosclerosis	0.0228	0.0908	CbGbCtD
Pomalidomide—CYP3A4—Ezetimibe—atherosclerosis	0.0228	0.0908	CbGbCtD
Pomalidomide—CYP3A4—Simvastatin—atherosclerosis	0.0212	0.0845	CbGbCtD
Pomalidomide—CYP3A4—Pravastatin—atherosclerosis	0.0208	0.0827	CbGbCtD
Pomalidomide—CYP3A4—Lovastatin—atherosclerosis	0.0208	0.0827	CbGbCtD
Pomalidomide—Thalidomide—NFKB1—atherosclerosis	0.00319	0.59	CrCbGaD
Pomalidomide—Interstitial lung disease—Ezetimibe—atherosclerosis	0.0017	0.016	CcSEcCtD
Pomalidomide—Respiratory tract infection—Pravastatin—atherosclerosis	0.00165	0.0155	CcSEcCtD
Pomalidomide—Interstitial lung disease—Simvastatin—atherosclerosis	0.00162	0.0152	CcSEcCtD
Pomalidomide—Interstitial lung disease—Pravastatin—atherosclerosis	0.00147	0.0138	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Lovastatin—atherosclerosis	0.00124	0.0117	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Niacin—atherosclerosis	0.00116	0.0109	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Pravastatin—atherosclerosis	0.00105	0.00987	CcSEcCtD
Pomalidomide—Thalidomide—TNF—atherosclerosis	0.000979	0.181	CrCbGaD
Pomalidomide—Neuropathy—Pravastatin—atherosclerosis	0.000974	0.00916	CcSEcCtD
Pomalidomide—Breast disorder—Rosuvastatin—atherosclerosis	0.000949	0.00893	CcSEcCtD
Pomalidomide—Muscular weakness—Rosuvastatin—atherosclerosis	0.000926	0.00871	CcSEcCtD
Pomalidomide—Pain in extremity—Lovastatin—atherosclerosis	0.00089	0.00837	CcSEcCtD
Pomalidomide—Atrial fibrillation—Simvastatin—atherosclerosis	0.000879	0.00826	CcSEcCtD
Pomalidomide—Pain in extremity—Ezetimibe—atherosclerosis	0.000873	0.00821	CcSEcCtD
Pomalidomide—Bronchitis—Rosuvastatin—atherosclerosis	0.000873	0.00821	CcSEcCtD
Pomalidomide—Atrial fibrillation—Niacin—atherosclerosis	0.000807	0.00759	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Rosuvastatin—atherosclerosis	0.000794	0.00746	CcSEcCtD
Pomalidomide—Breast disorder—Ezetimibe—atherosclerosis	0.000789	0.00742	CcSEcCtD
Pomalidomide—Urinary tract infection—Rosuvastatin—atherosclerosis	0.000787	0.0074	CcSEcCtD
Pomalidomide—Nasopharyngitis—Ezetimibe—atherosclerosis	0.000781	0.00734	CcSEcCtD
Pomalidomide—Lenalidomide—PTGS2—atherosclerosis	0.000776	0.143	CrCbGaD
Pomalidomide—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.00077	0.00724	CcSEcCtD
Pomalidomide—Muscular weakness—Ezetimibe—atherosclerosis	0.00077	0.00724	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.000766	0.0072	CcSEcCtD
Pomalidomide—Muscular weakness—Simvastatin—atherosclerosis	0.000734	0.00691	CcSEcCtD
Pomalidomide—Urinary retention—Niacin—atherosclerosis	0.000727	0.00684	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.000701	0.0066	CcSEcCtD
Pomalidomide—Dry skin—Niacin—atherosclerosis	0.000701	0.00659	CcSEcCtD
Pomalidomide—Bronchitis—Simvastatin—atherosclerosis	0.000692	0.00651	CcSEcCtD
Pomalidomide—Dry skin—Pravastatin—atherosclerosis	0.00069	0.00649	CcSEcCtD
Pomalidomide—Muscular weakness—Niacin—atherosclerosis	0.000674	0.00634	CcSEcCtD
Pomalidomide—Nasopharyngitis—Pravastatin—atherosclerosis	0.000673	0.00633	CcSEcCtD
Pomalidomide—Infestation NOS—Ezetimibe—atherosclerosis	0.000673	0.00633	CcSEcCtD
Pomalidomide—Infestation—Ezetimibe—atherosclerosis	0.000673	0.00633	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Lovastatin—atherosclerosis	0.000672	0.00632	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000669	0.00629	CcSEcCtD
Pomalidomide—Urinary tract infection—Lovastatin—atherosclerosis	0.000667	0.00627	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.000664	0.00624	CcSEcCtD
Pomalidomide—Muscular weakness—Pravastatin—atherosclerosis	0.000664	0.00624	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.00066	0.0062	CcSEcCtD
Pomalidomide—Mental disorder—Rosuvastatin—atherosclerosis	0.000637	0.00599	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000636	0.00598	CcSEcCtD
Pomalidomide—Bronchitis—Niacin—atherosclerosis	0.000636	0.00598	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000629	0.00591	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000605	0.00569	CcSEcCtD
Pomalidomide—Oedema peripheral—Ezetimibe—atherosclerosis	0.000595	0.0056	CcSEcCtD
Pomalidomide—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000594	0.00558	CcSEcCtD
Pomalidomide—Weight increased—Pravastatin—atherosclerosis	0.000592	0.00557	CcSEcCtD
Pomalidomide—Weight decreased—Pravastatin—atherosclerosis	0.000589	0.00554	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000569	0.00535	CcSEcCtD
Pomalidomide—Urinary tract infection—Pravastatin—atherosclerosis	0.000564	0.0053	CcSEcCtD
Pomalidomide—Chills—Lovastatin—atherosclerosis	0.000553	0.0052	CcSEcCtD
Pomalidomide—Cough—Rosuvastatin—atherosclerosis	0.000552	0.00519	CcSEcCtD
Pomalidomide—Angiopathy—Ezetimibe—atherosclerosis	0.000548	0.00515	CcSEcCtD
Pomalidomide—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000544	0.00512	CcSEcCtD
Pomalidomide—Arthralgia—Rosuvastatin—atherosclerosis	0.000539	0.00506	CcSEcCtD
Pomalidomide—Mental disorder—Ezetimibe—atherosclerosis	0.000529	0.00498	CcSEcCtD
Pomalidomide—Malnutrition—Ezetimibe—atherosclerosis	0.000526	0.00494	CcSEcCtD
Pomalidomide—Oedema peripheral—Niacin—atherosclerosis	0.000521	0.0049	CcSEcCtD
Pomalidomide—Confusional state—Rosuvastatin—atherosclerosis	0.000521	0.0049	CcSEcCtD
Pomalidomide—Back pain—Lovastatin—atherosclerosis	0.000519	0.00488	CcSEcCtD
Pomalidomide—Chills—Simvastatin—atherosclerosis	0.000517	0.00486	CcSEcCtD
Pomalidomide—Muscle spasms—Lovastatin—atherosclerosis	0.000515	0.00485	CcSEcCtD
Pomalidomide—Infection—Rosuvastatin—atherosclerosis	0.000513	0.00482	CcSEcCtD
Pomalidomide—Back pain—Ezetimibe—atherosclerosis	0.000509	0.00478	CcSEcCtD
Pomalidomide—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000506	0.00476	CcSEcCtD
Pomalidomide—Muscle spasms—Ezetimibe—atherosclerosis	0.000506	0.00475	CcSEcCtD
Pomalidomide—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000506	0.00475	CcSEcCtD
Pomalidomide—Mental disorder—Simvastatin—atherosclerosis	0.000505	0.00475	CcSEcCtD
Pomalidomide—Tremor—Lovastatin—atherosclerosis	0.000502	0.00472	CcSEcCtD
Pomalidomide—Anaemia—Ezetimibe—atherosclerosis	0.000486	0.00457	CcSEcCtD
Pomalidomide—Cardiac disorder—Pravastatin—atherosclerosis	0.000483	0.00455	CcSEcCtD
Pomalidomide—Muscle spasms—Simvastatin—atherosclerosis	0.000482	0.00453	CcSEcCtD
Pomalidomide—Vertigo—Lovastatin—atherosclerosis	0.000482	0.00453	CcSEcCtD
Pomalidomide—Angiopathy—Niacin—atherosclerosis	0.00048	0.00451	CcSEcCtD
Pomalidomide—Leukopenia—Lovastatin—atherosclerosis	0.00048	0.00451	CcSEcCtD
Pomalidomide—Chills—Niacin—atherosclerosis	0.000475	0.00446	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00047	0.00442	CcSEcCtD
Pomalidomide—Tremor—Simvastatin—atherosclerosis	0.00047	0.00442	CcSEcCtD
Pomalidomide—Chills—Pravastatin—atherosclerosis	0.000467	0.00439	CcSEcCtD
Pomalidomide—Insomnia—Rosuvastatin—atherosclerosis	0.000467	0.00439	CcSEcCtD
Pomalidomide—Thalidomide—PTGS2—atherosclerosis	0.000465	0.0859	CrCbGaD
Pomalidomide—Anaemia—Simvastatin—atherosclerosis	0.000463	0.00436	CcSEcCtD
Pomalidomide—Malnutrition—Niacin—atherosclerosis	0.00046	0.00433	CcSEcCtD
Pomalidomide—Cough—Ezetimibe—atherosclerosis	0.000459	0.00431	CcSEcCtD
Pomalidomide—Arthralgia—Lovastatin—atherosclerosis	0.000456	0.00429	CcSEcCtD
Pomalidomide—Anxiety—Lovastatin—atherosclerosis	0.000455	0.00428	CcSEcCtD
Pomalidomide—Vertigo—Simvastatin—atherosclerosis	0.000451	0.00424	CcSEcCtD
Pomalidomide—Leukopenia—Simvastatin—atherosclerosis	0.000449	0.00422	CcSEcCtD
Pomalidomide—Arthralgia—Ezetimibe—atherosclerosis	0.000448	0.00421	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000445	0.00418	CcSEcCtD
Pomalidomide—Muscle spasms—Niacin—atherosclerosis	0.000443	0.00416	CcSEcCtD
Pomalidomide—Pain—Rosuvastatin—atherosclerosis	0.000442	0.00415	CcSEcCtD
Pomalidomide—Constipation—Rosuvastatin—atherosclerosis	0.000442	0.00415	CcSEcCtD
Pomalidomide—Confusional state—Lovastatin—atherosclerosis	0.000441	0.00415	CcSEcCtD
Pomalidomide—PTGS2—leg—atherosclerosis	0.000439	0.151	CbGeAlD
Pomalidomide—Muscle spasms—Pravastatin—atherosclerosis	0.000436	0.0041	CcSEcCtD
Pomalidomide—Infection—Lovastatin—atherosclerosis	0.000435	0.00409	CcSEcCtD
Pomalidomide—Confusional state—Ezetimibe—atherosclerosis	0.000433	0.00407	CcSEcCtD
Pomalidomide—Thrombocytopenia—Lovastatin—atherosclerosis	0.000428	0.00403	CcSEcCtD
Pomalidomide—Arthralgia—Simvastatin—atherosclerosis	0.000427	0.00401	CcSEcCtD
Pomalidomide—Infection—Ezetimibe—atherosclerosis	0.000426	0.00401	CcSEcCtD
Pomalidomide—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000425	0.004	CcSEcCtD
Pomalidomide—Anxiety—Simvastatin—atherosclerosis	0.000425	0.004	CcSEcCtD
Pomalidomide—Tremor—Pravastatin—atherosclerosis	0.000425	0.00399	CcSEcCtD
Pomalidomide—Nervous system disorder—Ezetimibe—atherosclerosis	0.000421	0.00396	CcSEcCtD
Pomalidomide—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00042	0.00395	CcSEcCtD
Pomalidomide—Anaemia—Pravastatin—atherosclerosis	0.000419	0.00394	CcSEcCtD
Pomalidomide—Skin disorder—Ezetimibe—atherosclerosis	0.000417	0.00392	CcSEcCtD
Pomalidomide—Vertigo—Niacin—atherosclerosis	0.000414	0.00389	CcSEcCtD
Pomalidomide—Confusional state—Simvastatin—atherosclerosis	0.000413	0.00388	CcSEcCtD
Pomalidomide—Leukopenia—Niacin—atherosclerosis	0.000412	0.00388	CcSEcCtD
Pomalidomide—Vertigo—Pravastatin—atherosclerosis	0.000407	0.00383	CcSEcCtD
Pomalidomide—Infection—Simvastatin—atherosclerosis	0.000407	0.00382	CcSEcCtD
Pomalidomide—Leukopenia—Pravastatin—atherosclerosis	0.000406	0.00382	CcSEcCtD
Pomalidomide—Cough—Niacin—atherosclerosis	0.000402	0.00378	CcSEcCtD
Pomalidomide—Thrombocytopenia—Simvastatin—atherosclerosis	0.000401	0.00377	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000399	0.00375	CcSEcCtD
Pomalidomide—Insomnia—Lovastatin—atherosclerosis	0.000396	0.00372	CcSEcCtD
Pomalidomide—Cough—Pravastatin—atherosclerosis	0.000396	0.00372	CcSEcCtD
Pomalidomide—Arthralgia—Niacin—atherosclerosis	0.000392	0.00369	CcSEcCtD
Pomalidomide—PTGS2—hindlimb—atherosclerosis	0.000392	0.134	CbGeAlD
Pomalidomide—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000391	0.00368	CcSEcCtD
Pomalidomide—Dyspnoea—Lovastatin—atherosclerosis	0.00039	0.00367	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000389	0.00366	CcSEcCtD
Pomalidomide—Insomnia—Ezetimibe—atherosclerosis	0.000388	0.00365	CcSEcCtD
Pomalidomide—Arthralgia—Pravastatin—atherosclerosis	0.000386	0.00363	CcSEcCtD
Pomalidomide—Anxiety—Pravastatin—atherosclerosis	0.000385	0.00362	CcSEcCtD
Pomalidomide—Dyspnoea—Ezetimibe—atherosclerosis	0.000383	0.0036	CcSEcCtD
Pomalidomide—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00038	0.00358	CcSEcCtD
Pomalidomide—Decreased appetite—Lovastatin—atherosclerosis	0.00038	0.00358	CcSEcCtD
Pomalidomide—Fatigue—Lovastatin—atherosclerosis	0.000377	0.00355	CcSEcCtD
Pomalidomide—Constipation—Lovastatin—atherosclerosis	0.000374	0.00352	CcSEcCtD
Pomalidomide—Pain—Lovastatin—atherosclerosis	0.000374	0.00352	CcSEcCtD
Pomalidomide—Confusional state—Pravastatin—atherosclerosis	0.000373	0.00351	CcSEcCtD
Pomalidomide—Decreased appetite—Ezetimibe—atherosclerosis	0.000373	0.00351	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000373	0.00351	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000371	0.00348	CcSEcCtD
Pomalidomide—Asthenia—Rosuvastatin—atherosclerosis	0.00037	0.00348	CcSEcCtD
Pomalidomide—Insomnia—Simvastatin—atherosclerosis	0.00037	0.00348	CcSEcCtD
Pomalidomide—Fatigue—Ezetimibe—atherosclerosis	0.00037	0.00348	CcSEcCtD
Pomalidomide—Infection—Pravastatin—atherosclerosis	0.000368	0.00346	CcSEcCtD
Pomalidomide—Pain—Ezetimibe—atherosclerosis	0.000367	0.00345	CcSEcCtD
Pomalidomide—Constipation—Ezetimibe—atherosclerosis	0.000367	0.00345	CcSEcCtD
Pomalidomide—Pruritus—Rosuvastatin—atherosclerosis	0.000365	0.00343	CcSEcCtD
Pomalidomide—Skin disorder—Niacin—atherosclerosis	0.000365	0.00343	CcSEcCtD
Pomalidomide—Dyspnoea—Simvastatin—atherosclerosis	0.000365	0.00343	CcSEcCtD
Pomalidomide—Hyperhidrosis—Niacin—atherosclerosis	0.000363	0.00342	CcSEcCtD
Pomalidomide—Thrombocytopenia—Pravastatin—atherosclerosis	0.000362	0.00341	CcSEcCtD
Pomalidomide—Feeling abnormal—Lovastatin—atherosclerosis	0.000361	0.00339	CcSEcCtD
Pomalidomide—Hyperhidrosis—Pravastatin—atherosclerosis	0.000358	0.00336	CcSEcCtD
Pomalidomide—Decreased appetite—Simvastatin—atherosclerosis	0.000356	0.00335	CcSEcCtD
Pomalidomide—Feeling abnormal—Ezetimibe—atherosclerosis	0.000354	0.00333	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000353	0.00332	CcSEcCtD
Pomalidomide—Diarrhoea—Rosuvastatin—atherosclerosis	0.000353	0.00332	CcSEcCtD
Pomalidomide—Fatigue—Simvastatin—atherosclerosis	0.000353	0.00332	CcSEcCtD
Pomalidomide—Pain—Simvastatin—atherosclerosis	0.00035	0.00329	CcSEcCtD
Pomalidomide—Constipation—Simvastatin—atherosclerosis	0.00035	0.00329	CcSEcCtD
Pomalidomide—Body temperature increased—Lovastatin—atherosclerosis	0.000346	0.00325	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000342	0.00322	CcSEcCtD
Pomalidomide—Dizziness—Rosuvastatin—atherosclerosis	0.000341	0.00321	CcSEcCtD
Pomalidomide—Insomnia—Niacin—atherosclerosis	0.00034	0.0032	CcSEcCtD
Pomalidomide—Body temperature increased—Ezetimibe—atherosclerosis	0.000339	0.00319	CcSEcCtD
Pomalidomide—Feeling abnormal—Simvastatin—atherosclerosis	0.000337	0.00317	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000337	0.00317	CcSEcCtD
Pomalidomide—PTGS2—appendage—atherosclerosis	0.000336	0.115	CbGeAlD
Pomalidomide—Dyspnoea—Niacin—atherosclerosis	0.000335	0.00315	CcSEcCtD
Pomalidomide—Insomnia—Pravastatin—atherosclerosis	0.000335	0.00315	CcSEcCtD
Pomalidomide—Dyspnoea—Pravastatin—atherosclerosis	0.00033	0.0031	CcSEcCtD
Pomalidomide—Decreased appetite—Niacin—atherosclerosis	0.000327	0.00307	CcSEcCtD
Pomalidomide—Rash—Rosuvastatin—atherosclerosis	0.000326	0.00306	CcSEcCtD
Pomalidomide—Dermatitis—Rosuvastatin—atherosclerosis	0.000325	0.00306	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Niacin—atherosclerosis	0.000324	0.00305	CcSEcCtD
Pomalidomide—Body temperature increased—Simvastatin—atherosclerosis	0.000324	0.00304	CcSEcCtD
Pomalidomide—Headache—Rosuvastatin—atherosclerosis	0.000323	0.00304	CcSEcCtD
Pomalidomide—Hypersensitivity—Lovastatin—atherosclerosis	0.000322	0.00303	CcSEcCtD
Pomalidomide—Decreased appetite—Pravastatin—atherosclerosis	0.000322	0.00302	CcSEcCtD
Pomalidomide—Pain—Niacin—atherosclerosis	0.000321	0.00302	CcSEcCtD
Pomalidomide—Fatigue—Pravastatin—atherosclerosis	0.000319	0.003	CcSEcCtD
Pomalidomide—Pain—Pravastatin—atherosclerosis	0.000316	0.00298	CcSEcCtD
Pomalidomide—Constipation—Pravastatin—atherosclerosis	0.000316	0.00298	CcSEcCtD
Pomalidomide—Hypersensitivity—Ezetimibe—atherosclerosis	0.000316	0.00297	CcSEcCtD
Pomalidomide—Asthenia—Lovastatin—atherosclerosis	0.000314	0.00295	CcSEcCtD
Pomalidomide—Pruritus—Lovastatin—atherosclerosis	0.00031	0.00291	CcSEcCtD
Pomalidomide—Asthenia—Ezetimibe—atherosclerosis	0.000308	0.0029	CcSEcCtD
Pomalidomide—Nausea—Rosuvastatin—atherosclerosis	0.000307	0.00288	CcSEcCtD
Pomalidomide—Feeling abnormal—Pravastatin—atherosclerosis	0.000305	0.00287	CcSEcCtD
Pomalidomide—Pruritus—Ezetimibe—atherosclerosis	0.000304	0.00286	CcSEcCtD
Pomalidomide—Hypersensitivity—Simvastatin—atherosclerosis	0.000302	0.00284	CcSEcCtD
Pomalidomide—Diarrhoea—Lovastatin—atherosclerosis	0.000299	0.00282	CcSEcCtD
Pomalidomide—Body temperature increased—Niacin—atherosclerosis	0.000297	0.00279	CcSEcCtD
Pomalidomide—Asthenia—Simvastatin—atherosclerosis	0.000294	0.00276	CcSEcCtD
Pomalidomide—Diarrhoea—Ezetimibe—atherosclerosis	0.000294	0.00276	CcSEcCtD
Pomalidomide—Body temperature increased—Pravastatin—atherosclerosis	0.000292	0.00275	CcSEcCtD
Pomalidomide—Pruritus—Simvastatin—atherosclerosis	0.00029	0.00272	CcSEcCtD
Pomalidomide—Dizziness—Lovastatin—atherosclerosis	0.000289	0.00272	CcSEcCtD
Pomalidomide—Dizziness—Ezetimibe—atherosclerosis	0.000284	0.00267	CcSEcCtD
Pomalidomide—Diarrhoea—Simvastatin—atherosclerosis	0.00028	0.00263	CcSEcCtD
Pomalidomide—Vomiting—Lovastatin—atherosclerosis	0.000278	0.00262	CcSEcCtD
Pomalidomide—Hypersensitivity—Niacin—atherosclerosis	0.000277	0.0026	CcSEcCtD
Pomalidomide—Rash—Lovastatin—atherosclerosis	0.000276	0.00259	CcSEcCtD
Pomalidomide—Dermatitis—Lovastatin—atherosclerosis	0.000276	0.00259	CcSEcCtD
Pomalidomide—Headache—Lovastatin—atherosclerosis	0.000274	0.00258	CcSEcCtD
Pomalidomide—Vomiting—Ezetimibe—atherosclerosis	0.000273	0.00257	CcSEcCtD
Pomalidomide—Hypersensitivity—Pravastatin—atherosclerosis	0.000273	0.00256	CcSEcCtD
Pomalidomide—Dizziness—Simvastatin—atherosclerosis	0.000271	0.00254	CcSEcCtD
Pomalidomide—Rash—Ezetimibe—atherosclerosis	0.000271	0.00254	CcSEcCtD
Pomalidomide—Dermatitis—Ezetimibe—atherosclerosis	0.00027	0.00254	CcSEcCtD
Pomalidomide—CRBN—adipose tissue—atherosclerosis	0.00027	0.0928	CbGeAlD
Pomalidomide—Asthenia—Niacin—atherosclerosis	0.00027	0.00254	CcSEcCtD
Pomalidomide—Headache—Ezetimibe—atherosclerosis	0.000269	0.00253	CcSEcCtD
Pomalidomide—Pruritus—Niacin—atherosclerosis	0.000266	0.0025	CcSEcCtD
Pomalidomide—Asthenia—Pravastatin—atherosclerosis	0.000265	0.0025	CcSEcCtD
Pomalidomide—Pruritus—Pravastatin—atherosclerosis	0.000262	0.00246	CcSEcCtD
Pomalidomide—Vomiting—Simvastatin—atherosclerosis	0.00026	0.00245	CcSEcCtD
Pomalidomide—Nausea—Lovastatin—atherosclerosis	0.00026	0.00244	CcSEcCtD
Pomalidomide—Rash—Simvastatin—atherosclerosis	0.000258	0.00243	CcSEcCtD
Pomalidomide—Dermatitis—Simvastatin—atherosclerosis	0.000258	0.00242	CcSEcCtD
Pomalidomide—Diarrhoea—Niacin—atherosclerosis	0.000257	0.00242	CcSEcCtD
Pomalidomide—Headache—Simvastatin—atherosclerosis	0.000256	0.00241	CcSEcCtD
Pomalidomide—Nausea—Ezetimibe—atherosclerosis	0.000255	0.0024	CcSEcCtD
Pomalidomide—Diarrhoea—Pravastatin—atherosclerosis	0.000253	0.00238	CcSEcCtD
Pomalidomide—Dizziness—Niacin—atherosclerosis	0.000248	0.00234	CcSEcCtD
Pomalidomide—Dizziness—Pravastatin—atherosclerosis	0.000245	0.0023	CcSEcCtD
Pomalidomide—Nausea—Simvastatin—atherosclerosis	0.000243	0.00229	CcSEcCtD
Pomalidomide—PTGS2—artery—atherosclerosis	0.00024	0.0824	CbGeAlD
Pomalidomide—Vomiting—Niacin—atherosclerosis	0.000239	0.00225	CcSEcCtD
Pomalidomide—Rash—Niacin—atherosclerosis	0.000237	0.00223	CcSEcCtD
Pomalidomide—Dermatitis—Niacin—atherosclerosis	0.000237	0.00223	CcSEcCtD
Pomalidomide—Headache—Niacin—atherosclerosis	0.000235	0.00221	CcSEcCtD
Pomalidomide—Vomiting—Pravastatin—atherosclerosis	0.000235	0.00221	CcSEcCtD
Pomalidomide—Rash—Pravastatin—atherosclerosis	0.000233	0.00219	CcSEcCtD
Pomalidomide—Dermatitis—Pravastatin—atherosclerosis	0.000233	0.00219	CcSEcCtD
Pomalidomide—Headache—Pravastatin—atherosclerosis	0.000232	0.00218	CcSEcCtD
Pomalidomide—Nausea—Niacin—atherosclerosis	0.000223	0.0021	CcSEcCtD
Pomalidomide—Nausea—Pravastatin—atherosclerosis	0.00022	0.00207	CcSEcCtD
Pomalidomide—PTGS2—endothelium—atherosclerosis	0.000203	0.0696	CbGeAlD
Pomalidomide—CRBN—liver—atherosclerosis	0.00019	0.0651	CbGeAlD
Pomalidomide—PTGS2—blood vessel—atherosclerosis	0.000187	0.0642	CbGeAlD
Pomalidomide—ABCB1—blood vessel—atherosclerosis	0.000116	0.0397	CbGeAlD
Pomalidomide—PTGS2—connective tissue—atherosclerosis	9.59e-05	0.0329	CbGeAlD
Pomalidomide—PTGS2—cardiovascular system—atherosclerosis	8.34e-05	0.0287	CbGeAlD
Pomalidomide—PTGS2—adipose tissue—atherosclerosis	7.36e-05	0.0253	CbGeAlD
Pomalidomide—CYP1A2—liver—atherosclerosis	6.23e-05	0.0214	CbGeAlD
Pomalidomide—ABCB1—cardiovascular system—atherosclerosis	5.16e-05	0.0177	CbGeAlD
Pomalidomide—PTGS2—liver—atherosclerosis	5.16e-05	0.0177	CbGeAlD
Pomalidomide—ABCB1—adipose tissue—atherosclerosis	4.55e-05	0.0156	CbGeAlD
Pomalidomide—CYP3A4—liver—atherosclerosis	4.51e-05	0.0155	CbGeAlD
Pomalidomide—ABCB1—liver—atherosclerosis	3.19e-05	0.011	CbGeAlD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—atherosclerosis	2.05e-05	0.000183	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APOA2—atherosclerosis	2.02e-05	0.00018	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PLA2G2A—atherosclerosis	2.02e-05	0.00018	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALOX15—atherosclerosis	2.02e-05	0.00018	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALOX5AP—atherosclerosis	2.02e-05	0.00018	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ABCG5—atherosclerosis	2e-05	0.000178	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	2e-05	0.000178	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—PLAT—atherosclerosis	1.97e-05	0.000176	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	1.95e-05	0.000174	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	1.95e-05	0.000174	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CST3—atherosclerosis	1.95e-05	0.000173	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	1.94e-05	0.000173	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—LPA—atherosclerosis	1.93e-05	0.000172	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	1.93e-05	0.000172	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—atherosclerosis	1.92e-05	0.000171	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NFKB1—atherosclerosis	1.9e-05	0.000169	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	1.88e-05	0.000168	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—BGN—atherosclerosis	1.87e-05	0.000167	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.86e-05	0.000165	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APOA5—atherosclerosis	1.85e-05	0.000165	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NAMPT—atherosclerosis	1.84e-05	0.000164	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—LTA4H—atherosclerosis	1.82e-05	0.000163	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCG8—atherosclerosis	1.82e-05	0.000163	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APOC3—atherosclerosis	1.82e-05	0.000162	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LDLR—atherosclerosis	1.81e-05	0.000161	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ABCG1—atherosclerosis	1.81e-05	0.000161	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	1.8e-05	0.00016	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.8e-05	0.00016	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PLA2G1B—atherosclerosis	1.78e-05	0.000159	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—atherosclerosis	1.78e-05	0.000158	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.76e-05	0.000157	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	1.75e-05	0.000156	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HSPA1B—atherosclerosis	1.75e-05	0.000156	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.75e-05	0.000156	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.74e-05	0.000155	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	1.73e-05	0.000154	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—atherosclerosis	1.72e-05	0.000153	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALOX5—atherosclerosis	1.72e-05	0.000153	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—STAT3—atherosclerosis	1.7e-05	0.000152	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	1.7e-05	0.000152	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—FABP4—atherosclerosis	1.7e-05	0.000151	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—LCAT—atherosclerosis	1.7e-05	0.000151	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NCF1—atherosclerosis	1.69e-05	0.000151	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—PLG—atherosclerosis	1.68e-05	0.00015	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOA4—atherosclerosis	1.67e-05	0.000148	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP7A1—atherosclerosis	1.64e-05	0.000146	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MAPK3—atherosclerosis	1.63e-05	0.000145	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLTP—atherosclerosis	1.62e-05	0.000145	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	1.61e-05	0.000144	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CYBA—atherosclerosis	1.59e-05	0.000142	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.59e-05	0.000142	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TGFB1—atherosclerosis	1.58e-05	0.000141	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PARP1—atherosclerosis	1.56e-05	0.000139	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	1.55e-05	0.000138	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NAMPT—atherosclerosis	1.54e-05	0.000138	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.53e-05	0.000137	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—LIPC—atherosclerosis	1.53e-05	0.000137	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	1.53e-05	0.000136	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APOC3—atherosclerosis	1.52e-05	0.000136	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	1.52e-05	0.000135	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—LDLR—atherosclerosis	1.52e-05	0.000135	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP27A1—atherosclerosis	1.51e-05	0.000135	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	1.48e-05	0.000132	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	1.48e-05	0.000132	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CETP—atherosclerosis	1.48e-05	0.000132	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	1.45e-05	0.000129	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCG1—atherosclerosis	1.44e-05	0.000128	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PLA2G2A—atherosclerosis	1.43e-05	0.000128	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALOX15—atherosclerosis	1.43e-05	0.000128	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALOX5AP—atherosclerosis	1.43e-05	0.000128	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOA2—atherosclerosis	1.43e-05	0.000128	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ABCG5—atherosclerosis	1.42e-05	0.000126	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SCARB1—atherosclerosis	1.42e-05	0.000126	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCG8—atherosclerosis	1.41e-05	0.000125	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LTA4H—atherosclerosis	1.41e-05	0.000125	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	1.38e-05	0.000123	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.38e-05	0.000123	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—LPA—atherosclerosis	1.37e-05	0.000122	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—FABP4—atherosclerosis	1.36e-05	0.000121	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—LCAT—atherosclerosis	1.36e-05	0.000121	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HMGCR—atherosclerosis	1.34e-05	0.000119	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOA4—atherosclerosis	1.33e-05	0.000119	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—BGN—atherosclerosis	1.33e-05	0.000118	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOA5—atherosclerosis	1.31e-05	0.000117	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP7A1—atherosclerosis	1.31e-05	0.000116	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PLA2G1B—atherosclerosis	1.26e-05	0.000113	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.25e-05	0.000111	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	1.25e-05	0.000111	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALOX5—atherosclerosis	1.22e-05	0.000109	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP27A1—atherosclerosis	1.21e-05	0.000108	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ABCA1—atherosclerosis	1.19e-05	0.000106	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—atherosclerosis	1.19e-05	0.000106	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	1.19e-05	0.000106	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.17e-05	0.000105	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APOB—atherosclerosis	1.17e-05	0.000104	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	1.16e-05	0.000103	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	1.15e-05	0.000102	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALOX15—atherosclerosis	1.15e-05	0.000102	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	1.15e-05	0.000102	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOA2—atherosclerosis	1.15e-05	0.000102	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCG5—atherosclerosis	1.13e-05	0.000101	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	1.13e-05	0.000101	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LPL—atherosclerosis	1.12e-05	9.96e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.11e-05	9.91e-05	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—atherosclerosis	1.1e-05	9.79e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NAMPT—atherosclerosis	1.09e-05	9.75e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—LPA—atherosclerosis	1.09e-05	9.73e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—LIPC—atherosclerosis	1.09e-05	9.69e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PRKCG—atherosclerosis	1.09e-05	9.68e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOC3—atherosclerosis	1.08e-05	9.63e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—LDLR—atherosclerosis	1.07e-05	9.57e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—BGN—atherosclerosis	1.06e-05	9.43e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.05e-05	9.36e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CETP—atherosclerosis	1.05e-05	9.35e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOA5—atherosclerosis	1.05e-05	9.33e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LCAT—atherosclerosis	1.05e-05	9.32e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—FABP4—atherosclerosis	1.05e-05	9.32e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	1.03e-05	9.18e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOA4—atherosclerosis	1.03e-05	9.15e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HMOX1—atherosclerosis	1.02e-05	9.12e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.02e-05	9.07e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.01e-05	8.99e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	1.01e-05	8.98e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTHFR—atherosclerosis	1.01e-05	8.97e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SCARB1—atherosclerosis	1e-05	8.95e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	9.97e-06	8.88e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	9.88e-06	8.8e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	9.86e-06	8.78e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APOB—atherosclerosis	9.8e-06	8.73e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PDGFB—atherosclerosis	9.8e-06	8.73e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALOX5—atherosclerosis	9.74e-06	8.68e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTM1—atherosclerosis	9.54e-06	8.5e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HMGCR—atherosclerosis	9.49e-06	8.45e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APOE—atherosclerosis	9.37e-06	8.35e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—LPL—atherosclerosis	9.36e-06	8.34e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP27A1—atherosclerosis	9.32e-06	8.31e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	9.3e-06	8.29e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CAV1—atherosclerosis	9.28e-06	8.27e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APOA1—atherosclerosis	9.26e-06	8.25e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GPX1—atherosclerosis	9.13e-06	8.14e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	9e-06	8.02e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CD36—atherosclerosis	8.89e-06	7.92e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	8.84e-06	7.88e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALOX15—atherosclerosis	8.84e-06	7.88e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	8.84e-06	7.88e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOA2—atherosclerosis	8.84e-06	7.88e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NAMPT—atherosclerosis	8.74e-06	7.78e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCG5—atherosclerosis	8.73e-06	7.78e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS2—atherosclerosis	8.73e-06	7.78e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	8.68e-06	7.74e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—LIPC—atherosclerosis	8.68e-06	7.73e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOC3—atherosclerosis	8.63e-06	7.69e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—LDLR—atherosclerosis	8.57e-06	7.64e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ABCA1—atherosclerosis	8.46e-06	7.53e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LPA—atherosclerosis	8.43e-06	7.51e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTHFR—atherosclerosis	8.43e-06	7.51e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CETP—atherosclerosis	8.38e-06	7.46e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARA—atherosclerosis	8.27e-06	7.37e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—BGN—atherosclerosis	8.17e-06	7.28e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOA5—atherosclerosis	8.09e-06	7.2e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SCARB1—atherosclerosis	8.02e-06	7.15e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AGT—atherosclerosis	8.01e-06	7.13e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—INS—atherosclerosis	8e-06	7.13e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APOE—atherosclerosis	7.85e-06	6.99e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	7.81e-06	6.96e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	7.78e-06	6.93e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CAV1—atherosclerosis	7.77e-06	6.93e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APOA1—atherosclerosis	7.76e-06	6.91e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HMGCR—atherosclerosis	7.57e-06	6.75e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALOX5—atherosclerosis	7.52e-06	6.7e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SERPINE1—atherosclerosis	7.35e-06	6.55e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HMOX1—atherosclerosis	7.26e-06	6.46e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CG—atherosclerosis	7.08e-06	6.31e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS3—atherosclerosis	7.02e-06	6.25e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOB—atherosclerosis	6.95e-06	6.19e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARG—atherosclerosis	6.83e-06	6.09e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.83e-06	6.09e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTM1—atherosclerosis	6.76e-06	6.02e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCA1—atherosclerosis	6.75e-06	6.01e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NAMPT—atherosclerosis	6.74e-06	6.01e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—INS—atherosclerosis	6.7e-06	5.97e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LIPC—atherosclerosis	6.7e-06	5.97e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOC3—atherosclerosis	6.66e-06	5.93e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—LPL—atherosclerosis	6.64e-06	5.91e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LDLR—atherosclerosis	6.62e-06	5.9e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GPX1—atherosclerosis	6.47e-06	5.77e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CETP—atherosclerosis	6.46e-06	5.76e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CD36—atherosclerosis	6.3e-06	5.62e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SCARB1—atherosclerosis	6.19e-06	5.51e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALB—atherosclerosis	6.15e-06	5.47e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTHFR—atherosclerosis	5.97e-06	5.32e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NOS3—atherosclerosis	5.88e-06	5.24e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARA—atherosclerosis	5.86e-06	5.22e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.85e-06	5.21e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HMOX1—atherosclerosis	5.79e-06	5.16e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AGT—atherosclerosis	5.68e-06	5.06e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOE—atherosclerosis	5.56e-06	4.96e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOB—atherosclerosis	5.55e-06	4.94e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CAV1—atherosclerosis	5.51e-06	4.91e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOA1—atherosclerosis	5.5e-06	4.9e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTM1—atherosclerosis	5.4e-06	4.81e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—LPL—atherosclerosis	5.3e-06	4.72e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCA1—atherosclerosis	5.21e-06	4.64e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GPX1—atherosclerosis	5.17e-06	4.6e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CD36—atherosclerosis	5.03e-06	4.48e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CG—atherosclerosis	5.02e-06	4.47e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—atherosclerosis	5.01e-06	4.46e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARG—atherosclerosis	4.84e-06	4.32e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAPK3—atherosclerosis	4.78e-06	4.26e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTHFR—atherosclerosis	4.77e-06	4.25e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—INS—atherosclerosis	4.75e-06	4.23e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARA—atherosclerosis	4.68e-06	4.17e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—atherosclerosis	4.64e-06	4.14e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AGT—atherosclerosis	4.53e-06	4.04e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.47e-06	3.98e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOE—atherosclerosis	4.44e-06	3.96e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CAV1—atherosclerosis	4.4e-06	3.92e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOA1—atherosclerosis	4.39e-06	3.91e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALB—atherosclerosis	4.36e-06	3.88e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOB—atherosclerosis	4.28e-06	3.81e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NOS3—atherosclerosis	4.17e-06	3.71e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.17e-06	3.71e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LPL—atherosclerosis	4.09e-06	3.64e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CG—atherosclerosis	4.01e-06	3.57e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GPX1—atherosclerosis	3.99e-06	3.55e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CD36—atherosclerosis	3.88e-06	3.46e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARG—atherosclerosis	3.87e-06	3.45e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—atherosclerosis	3.81e-06	3.4e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—INS—atherosclerosis	3.79e-06	3.38e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.68e-06	3.28e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARA—atherosclerosis	3.61e-06	3.22e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AGT—atherosclerosis	3.5e-06	3.12e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—atherosclerosis	3.5e-06	3.12e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALB—atherosclerosis	3.48e-06	3.1e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOE—atherosclerosis	3.43e-06	3.05e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CAV1—atherosclerosis	3.4e-06	3.02e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOA1—atherosclerosis	3.39e-06	3.02e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NOS3—atherosclerosis	3.33e-06	2.96e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—atherosclerosis	3.23e-06	2.87e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.09e-06	2.76e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—atherosclerosis	3.04e-06	2.71e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARG—atherosclerosis	2.98e-06	2.66e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—INS—atherosclerosis	2.93e-06	2.61e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—atherosclerosis	2.7e-06	2.41e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALB—atherosclerosis	2.68e-06	2.39e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NOS3—atherosclerosis	2.57e-06	2.29e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.35e-06	2.09e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—atherosclerosis	1.92e-06	1.71e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—atherosclerosis	1.53e-06	1.36e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—atherosclerosis	1.18e-06	1.05e-05	CbGpPWpGaD
